Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483578 | 0.88 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL507445 | 0.86 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL13947349 | 0.86 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL11666172 | 0.86 | CNR1 (0.67) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL1394203 | 0.86 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL11625676 | 0.85 | LMNA (0.74) | RAB9ANPC1SMN1; SMN2NAMPTHTT | |
| SCHEMBL19226501 | 0.85 | TAS1R3 (0.70) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL11627869 | 0.83 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL16838904 | 0.83 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2GAANAMPT | |
| SCHEMBL17886760 | 0.83 | ALDH1A1 (0.73) | RAB9ANPC1SMN1; SMN2GAANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | RAB9A 4382/4885NPC1 100/4885SMN1; SMN2 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.